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Abstract
Background: Tumor necrosis factor alpha (TNF-α) is thought to be involved in the various immunogenetic events that 
influence HIV-1 infection.
Methods: We aimed to determine whether carriage of the TNF-α-238G>A, -308G>A and -863 C>A gene promoter single 
nucleotide polymorphisms (SNP) and the CCR5Δ32 variant allele influence the risk of HIV-1 infection and disease 
progression in Caucasian Spaniards. The study group consisted of 423 individuals. Of these, 239 were uninfected (36 
heavily exposed but uninfected [EU] and 203 healthy controls [HC]) and 184 were HIV-1-infected (109 typical 
progressors [TP] and 75 long-term nonprogressors [LTNP] of over 16 years' duration). TNF-α SNP and the CCR5Δ32 allele 
were assessed using PCR-RFLP and automatic sequencing analysis methods on white blood cell DNA. Genotype and 
allele frequencies were compared using the χ 2 test and the Fisher exact test. Haplotypes were compared by logistic 
regression analysis.
Results: The distribution of TNF-α-238G>A, -308G>A and -863 C>A genetic variants was non-significantly different in 
HIV-1-infected patients compared with uninfected individuals: -238G>A, p = 0.7 and p = 0.3; -308G>A, p = 0.05 and p = 
0.07; -863 C>A, p = 0.7 and p = 0.4, for genotype and allele comparisons, respectively. Haplotype analyses, however, 
indicated that carriers of the haplotype H3 were significantly more common among uninfected subjects (p = 0.04). 
Among the infected patients, the distribution of the three TNF-α genetic variants assessed was non-significantly 
different between TP and LTNP: -238G>A, p = 0.35 and p = 0.7; -308G>A, p = 0.7 and p = 0.6: -863 C>A, p = 0.2 and p = 
0.2, for genotype and allele comparisons, respectively. Haplotype analyses also indicated non-significant associations. 
Subanalyses in the LTNP subset indicated that the TNF-α-238A variant allele was significantly overrepresented in 
patients who spontaneously controlled plasma viremia compared with those who had a detectable plasma viral load 
(genotype comparisons, p = 0.02; allele comparisons, p = 0.03). The CCR5Δ32 distribution was non-significantly 
different in HIV-1-infected patients with respect to the uninfected population (p = 0.15 and p = 0.2 for genotype and 
allele comparisons, respectively) and in LTNP vs TP (p = 0.4 and p = 0.5 for genotype and allele comparisons, 
respectively).
Conclusions: In our cohort of Caucasian Spaniards, TNF-α genetic variants could be involved in the vulnerability to HIV-
1 infection. TNF-α genetic variants were unrelated to disease progression in infected subjects. The -238G>A SNP may 
modulate the control of viremia in LTNP. Carriage of the CCR5Δ32 variant allele had no effect on the risk of infection and 
disease progression.
Background
TNF-α is a pleiotropic cytokine that acts as an immune
and inflammatory mediator. It is synthesized mainly by
macrophages and T-cells and most of its actions take
place by binding to two cell receptors: TNF-α R1 and R2
[1]. Investigations suggest that TNF-α is involved in the
pathogenesis of HIV-1 infection since it is overproduced
by infected individuals [2-4].
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Like many other proinflammatory cytokines, the pro-
duction of TNF-α is at least partially genetically deter-
mined [5,6]. Several functional single nucleotide
polymorphisms (SNP) have been identified within the
TNF-α  gene cluster [5-8], the most widely studied of
which are a G>A transition at position -238, a G>A tran-
sition at position -308, and a C>A transition at position -
863 [9]. Several cohort studies have assessed the influ-
ence of TNF-α  SNP on the immunogenetics of HIV-1
infection. The information available on how TNF-α
genetic variants affect vulnerability to infection is incon-
sistent [10-14]: some studies have found no effect
[11,13,14] while others have found a strong association
[10,12]. Case-control studies have assessed the influence
of TNF-α genetic variants on HIV-1 disease progression
in infected patients [10-12,14-17]. While some of these
studies have reported an association with progression
[10-12,16,17], others have failed to find such an associa-
tion [14,15]. A minority of untreated HIV-1-infected
patients show an uncommon clinical form of infection
characterized by a non-progressive disease and, some-
times, by self-limited viremia over the years. These
patients are known as long-term nonprogressors (LTNP)
[18] and elite controllers [19], respectively. Little data is
available on the influence of TNF-α SNP on these uncom-
mon clinical forms of HIV-1 infection [11,16].
In this study we have assessed the influence of TNF-α
SNP on the vulnerability to HIV-1 infection and, in
infected patients, on disease progression. For this pur-
pose we analysed a cohort that we have already used for
several immunogenetic studies on HIV-1 infection which
contains a subset of repeatedly exposed but uninfected
individuals and a carefully collected cohort of extreme
long-term nonprogressors [20,21]. Given its modulating
role in HIV-1-infection and disease progression reported
elsewhere [22], the CCR5Δ32 allele was also assessed.
Methods
Design and setting
This was a multicenter cross-sectional population associ-
ation study. All subjects were recruited from a prospec-
tively collected cohort of almost 6000 HIV-1-infected
patients treated at the HIV outpatients' clinics of the par-
ticipating hospitals, which are located in an epidemiolog-
ical setting in which intravenous drug use is one of the
main causes of HIV-1-infection.
Population
Two subsets of HIV-1-infected patients were studied:
LTNP and typical progressors (TP). They were recruited
between 2005 and 2007. Criteria for LTNP were: asymp-
tomatic HIV-1 infection of over 16 years' duration; in the
absence of any antiretroviral treatment, a stable CD4+
cell count persistently over 500 cells/μl; and a plasma
HIV-1 viral load repeatedly under 5000 copies/ml [18].
LTNP were further divided into two subgroups depend-
ing on whether the plasma viral load was detectable
(LTNP-DVL) or persistently undetectable. LTNP in the
latter subgroup were called elite controllers (LTNP-EC)
[19]. Patients were categorized as TP if they fulfilled all
the following criteria: a) the HIV-1 infection had pro-
gressed to the advanced disease (that is to say class C
HIV-1 disease had appeared according to the 1993 Cen-
ters for Disease Control criteria [23]), b) the plasma HIV-
1 viral load was over 35,000 copies/ml and, c) the CD4+
T-cell count decreased over time and was below 350 cells/
μl at least once in the first 10 years of infection. Almost all
of them were on antiretroviral therapy when they
enrolled. For a few patients whose date of infection was
not available, we assumed that it was the midpoint
between the first positive and the last negative HIV-1
blood test [24,25]. W e identified 75 patients within our
cohort who fulfilled the LTNP criteria. They all agreed to
participate in the study, and we recruited a randomly
selected group of TP (n = 109) whose age (± 5 years) and
gender were comparable with the L TNP . A group of 36
repeatedly exposed but uninfected individuals (EU) was
also evaluated. They were part of a cohort of individuals
that we have used in other studies and whose details and
characteristics we have extensively described elsewhere
[26,27]. For the control group we studied a sample of
healthy subjects recruited from voluntary blood donors,
whose age and gender were comparable with the patients.
Table 1 shows details of the study population. All subjects
in our study were white Spaniards. Immigrants from
other countries, including those from other European
countries, and their descendents were excluded.
Informed consent was obtained from each participant.
The project was approved by the local ethical research
committees.
DNA and plasma samples
Blood samples with ethylene diamine tetra-acetic acid
were obtained from an antecubital vein. Five mL of whole
blood was used to determine the CD4+ T-cell count, and
500 μl was used to isolate DNA with a MagNa Pure LC
Instrument (Roche Diagnostics, Basel, Switzerland).
Plasma for determining HIV-1 viral load was obtained by
centrifugation at 3500 g for 15 minutes at 4C°.
Laboratory methods
HIV-1 infection
This was diagnosed using an enzymoimmunoanalysis
and confirmed by a Western-Blot test.
Plasma HIV-1 viral load
This was determined by the HIV Cobas Ampliprep CAP-
CTMHIV-1 using the COBAS AMPLICOR systemVeloso et al. BMC Medical Genetics 2010, 11:63
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(Roche Diagnostics, Basel, Switzerland). The cutoff for
undetectable viral load was 50 copies/μl.
Assessment of blood CD4+ T-cell count
Samples were analyzed in a flow cytometer FAC Scan
(Becton Dickinson Immunocytometry Systems, San José,
CA, USA). The data acquired were analyzed using the
Multiset program.
TNF-α genotype
-238 TNF-α genotype (rs 361525)
This polymorphism consists of a GT A substitution at
position -238 in the proximal promoter of the TNF-α
gene. The primers used in PCR were: forward primer 5'
AGAAGACCCCCCTCGGAACC3', modified in 3' for
RFLP analysis with Msp I restriction endonuclease, and
reverse primer 5' ATCTGGAGGAAGCGGTAGTG 3'. A
fragment of 152 bp was amplified at a final volume of 50
μL, with 3 mM of MgCl2, 0.2 mM dNTPs, 0.2 μM of each
primer and 1 unit of Taq polymerase. DNA was amplified
for 35 cycles: 95° for 30 seconds, 55° for 30 seconds and
72° for 30 seconds. PCR products were digested with
MspI and revealed a fragment of 152 bp for the A allele
and two fragments of 133 and 19 bp for the G allele.
-308 TNF-α genotype (rs 1800629)
This polymorphism consists of a GT A substitution at
position -308 in the proximal promoter of the TNF-α
gene. The primers used in the PCR were
5'AGGCAATAGGTTTTGAGGGCCAT3' and 5'TCCT
CCCTGCTCCGATTCCG3'. Amplification was per-
formed at a final volume of 50 μl containing 3 mM MgCl2,
Table 1: Demographic and clinical characteristics of the population analysed
Variable Healthy controls
(n = 203)
EU
(n = 36)
HIV-1 TP#
(n = 109)
HIV-1 LTNP#
(n = 75)
p value
Male (%) 146 (72%) 22 (61%) 78 (71.5%) 50 (66.6%) 0.59*
Age (years)
(mean ± SD)
44.2 ± 9.9 46.7 ± 9.2 41.8 ± 8.9 41.6 ± 7.1 0.39**
Duration of HIV-1 infection
(mean ± SD)
- - 6.2 ± 2.7 18.2 ± 1.6 < 0.0001
##, ***
Time span between 
documented infection and 
the onset of antiretroviral 
treatment
(mean ± SD)
- - 4.8 ± 1.3 - -
Plasma HIV-1 RNA (copies/ml)
(median and range)
- - 11,808
(<50->750,000)
267
(<50-4,600)
< 0.0001
##, ****
CD4+ T-cell count (cells/μl)
(median and range)
- - 478
(6-1404)
772
(503-2080)
< 0.0001 
##,****
Exposure to HIV-1 - 22 (61%) 61 (56%) 47 (62.7%) 0.64*
Parenteral - 14 (39%) 39 (35.8%) 22 (29.3%) 0.53*
Sexual - - 9 (8.2%) 6 (8%) 0.82*
Other
• EU: Individuals repeatedly exposed to HIV-1 but uninfected
• HIV-1 TP: HIV-1-infected typical progressors
• HIV-1 LTNP: HIV-1-infected long-term non-progressors
• <50 was arbitrarily counted as 49
# The studies made of HIV-1 TP and HIV-1 LTNP were cross-sectional and the viral load and CD4 cell counts are those of the date of selection. 
More than 90% of HIV-1 TP were under highly active antiretroviral therapy.
## p value stems from the comparison between HIV-1 TP and HIV-1 LTNP.
* p value results of the χ2 test;
** p value results of the ANOVA test
*** p value results of the Student T test
**** p value results of the Mann-Whitney U testVeloso et al. BMC Medical Genetics 2010, 11:63
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0.5 mM of each nucleotide (Boehringer Mannheim™,
Manheim, Germany), 0.2 μl of each oligonucleotide and 1
U of Taq polymerase (Gibco BRL). DNA was amplified
for 35 cycles with denaturation at 94°C for 1 minute
(min), annealing at 60°C for 1 min and extension at 72°C
for 1 min. The first cycle was at 94°C for 3 min, at 60°C
for 1 min and at 72°C for 1 min, followed by the 35 cycles
and, finally, a cycle at 94°C for 1 min, at 60°C for 1 min
and at 72°C for 5 min. The PCR products were digested at
37°C with NcoI for 24 hours, subjected to 2.5% agarose
gel electrophoresis at 80 V and stained with ethidium
bromide. The 107 bp band corresponded to the A allele
and the set of 87 bp and 20 bp bands corresponded to the
G allele.
-863 TNF-α genotype (rs 1800630)
This polymorphism consists of a CT A substitution at
position -863 in the proximal promoter of the TNF-α
gene. The primers used in the PCR were
5'GGCTCTGAGGAATGGGTTAC3' and 5'CTACAT
GGCCCTGTCTTCGTTACG3'. Amplification was per-
formed at a final volume of 25 μl containing 1 mM MgCl2,
0.2 mM of each nucleotide (Boehringer Mannheim™,
Manheim, Germany), 1.2 μl of each oligonucleotide and
0.5 U of Taq polymerase (Gibco BRL). DNA was ampli-
fied for 35 cycles with denaturation at 94°C for 30 sec-
onds, annealing at 62.3°C for 1 min and extension at 72°C
for 2 min. The first cycle was at 94°C for 3 min, followed
by the 35 cycles and, finally, an extension at 72°C for 5
min. The amplified product was digested with Bsa AI
restriction enzyme (New England Biolabs) at 37°C for 24
hours, electrophoresed on 2.5% agarose gel at 80 V and
stained with ethidium bromide. The 126 pb band corre-
sponded to the C wild-type allele and the set of 103 bp
and 23 pb bands corresponded to the variant A allele.
CCR5Δ32 genotype
The PCR primers used were 5'GCTCTCTCCCAGGAA
TCATC3' and antisense 5'TTCCCGAGTAGCAGAT
GACC3' with annealing at 60°C. The Genbank accession
number was AF031237.1. The PCR products were visual-
ized on 2.5% agarose gel. The wild-type CCR5 gene led to
a 174 bp fragment and the CCR5Δ32 variant resulted in a
142 bp fragment.
Statistical analysis
Descriptive data were expressed as the mean ± SD or
median (range) for non-parametric distributions. The
differences in levels between groups in continuous vari-
ables were compared using Student's t test, the Mann-
Whitney U test, or ANOVA when necessary. To evaluate
the association between HIV-1 TP and the different cate-
gories of uninfected subjects for the different genotypes,
the odds ratio (OR) and 95% confidence interval (95%CI)
were calculated. The Hardy-Weinberg equilibrium was
assessed by the chi-square goodness-of-fit test. Genotype
distribution and allele frequencies in the different groups
were compared by the χ2 test or Fisher's exact test when
necessary. To evaluate the association of TNF-α genetic
variants and CCR5Δ32 with the risk of HIV-1 infection,
the differences in the distribution between HIV-1-
infected, HC and EU were assessed. To evaluate the asso-
ciation of TNF-α genetic variants and CCR5Δ32 with dis-
ease progression in infected subjects, we compared HIV-
1-infected TP vs HIV-1-infected LTNP. In the latter sub-
set, we also compared LTNP-DVL and LTNP-EC. Analy-
ses were performed using the SPSS/PC+ statistical
package (v. 12.0 for Windows; Chicago, Illinois, USA).
Haplotype frequencies were estimated by the maximum-
likelihood method. Haplotype frequencies were esti-
mated by the PAC-likelihood method [28], which takes
into account the similarity of haplotypes and the fact that
linkage disequilibrium decays with distance. The distri-
butions of the different haplotypes between groups were
compared by logistic regression analysis. The commonest
haplotype (which we arbitrarily called haplotype H1) was
taken as a reference. Haplotype analyses were performed
using the PHASEv2.1 software [29,30]. A p value < 0.05
was considered significant.
Results
Four hundred and twenty-three individuals were studied:
239 uninfected (203 healthy controls [HC] and 36 EU)
and 184 HIV-1-infected. Of the infected individuals, most
of whom had acquired HIV-1 through intravenous drug
use, 109 were TP and 75 were LTNP. Of the LTNP, 20
were elite controllers. The age, gender and risk factors of
acquiring HIV-1 infection in the TP and LTNP were not
significantly different. Most TP (>90%) were receiving
highly active antiretroviral therapy. Table 1 shows
selected characteristics of the population studied. As
expected, the duration of HIV-1 infection was signifi-
cantly greater in L TNP than in TP . CD4+ T-cell counts
were also greater and viral loads were lower.
TNF-α gene polymorphisms
Tables 2 and 3 show the genotype distribution and allele
frequencies of the TNF-α-238G>A, -308G>A and  -863
C>A gene promoter SNP and the CCR5Δ32 allele for the
control group and the different patient categories. The
genotype distribution in control subjects, EU, HIV-1-
infected, HIV-1 TP and HIV-1 LTNP fits the expected
Hardy-Weinberg equilibrium for each TNF-α SNP.
The risk of infection showed no significant associations
with the TNF-α-238G>A and -863G>C SNP; carriers of
the  TNF-α-308A  genetic variant were overrepresented
among uninfected individuals, but the differences did not
reach statistical significance (genotype comparisons, p =
0.05; allele comparisons, p = 0.07) (Table 2).Veloso et al. BMC Medical Genetics 2010, 11:63
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Table 2: TNF-α and CCR5Δ32 genotype and allele frequencies in HC, EU and HIV-1-infected for assessment of associations 
with the risk of HIV-1 infection.
Genotype and allele 
frequencies
HC
(n = 203)
EU
(n = 36)
HIV-1-infected
(n = 184)
p value *
TNF-α-238 G>A
GG 147 (87.5%) 29 (80.5%) 161 (87.5%)
GA 20 (12%) 6 (16.7%) 22 (12%) 0.7
AA 1 (0.5%) 1 (2.8%) 1 (0.5%)
GA+AA 21 (12.5%) 7 (19.5%) 23 (12.5%) 0.5
Variant allele A 22 (6.5%) 8 (11.1%) 24 (6.5%) 0.3
TNF-α-308G>A
GG 122(70.9%) 24 (67%) 148 (80.4%)
GA 42(24.4%) 12 (33%) 31 (16.8%) 0.05
AA 8 (4.7%) 0 5 (2.8%)
GA+AA 50 (29.1%) 12 (33%) 36 (19.6%) 0.05
Variant allele A 58 (16.9%) 12 (16.7%) 41 (11.1%) 0.07
TNF-α-863 C>A
CC 116 (69.9%) 27 (75%) 137 (74.4%)
CA 44 (26.5%) 8 (22%) 45 (24.5%) 0.7
AA 6 (3.6%) 1 (3%) 2 (1.1%)
CA+AA 50 (30.1%) 9 (25%) 47 (25.5%) 0.6
Variant allele A 56 (16.8%) 10 (14%) 49 (13.3%) 0.4
CCR5Δ32
wt/wt 174 (87%) 31 (86.1%) 144 (78.3%)
wt/Δ32 26 (13%) 5 (13.9%) 40 (21.7%) 0.15
Δ32/Δ32 000
Δ32 allele 26 (6.5%) 5 (6.9) 40 (10.9%) 0.2
• HC: healthy controls
• EU: individuals repeatedly exposed to HIV-1 but uninfected
• wt indicates wild-type allele; Δ32, 32 bp deletion
• Genotype and allele numbers do not match the HC studied because DNA for TNF-α and CCR5 genotyping was not available or could not be 
amplified in some people
* χ2 test or Fisher exact test when necessary. p value arises from the comparison between HC, EU and HIV-1-infected.Veloso et al. BMC Medical Genetics 2010, 11:63
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Table 3: TNF-α and CCR5Δ32 genotype and allele frequencies in the different subsets of HIV-1-infected patients for 
assessment of associations with disease progression.
Genotype and
allele frequencies
HIV-1 TP
(n = 109)
HIV-1 LTNP
(n = 75)
p value * HIV-1 LNTP-DVL
(n = 55)
HIV-1 LTNP-EC
(n = 20)
p value **
TNF-α-238G>A
GG 97 (90%) 64 (85.3%) 50 (90.9%) 14 (70%)
GA 11 (10%) 11 (14.7%) 0.35 5 (9.1%) 6 (30%) 0.02
AA 1 (1%) 0 0 0
GA+AA 12 (11%) 11 (14.7%) 0.6 5 (9.1%) 6 (30%) 0.02
Variant allele A 13 (6%) 11 (7.3%) 0.7 5 (4.5%) 6 (15%) 0.03
TNF-α-308 G>A
GG 86 (78.9%) 62 (82.7%) 46 (83.6%) 16 (80%)
GA 20 (18.3%) 11 (14.7%) 0.7 8 (14.5%) 3 (15%) 0.7
AA 3 (2.8%) 2 (2.6%) 1 (1.9%) 1 (5%)
GA+AA 23 (21.1%) 13 (17.3%) 0.5 9 (16.4%) 4 (20%) 0.7
Variant allele A 26 (11.9%) 15 (10%) 0.6 10 (9.1%) 5 (12.5%) 0.7
TNF-α-863 C>A
CC 84 (77.1%) 53 (70.6%) 37 (67.3%) 16 (80%)
CA 25 (22.9%) 20 (26.6%) 0.2 17 (30.9%) 3 (15%) 0.3
AA 0 2 (2.8%) 1 (1.8%) 1 (5%)
CA+AA 25 (22.9%) 22 (29.3%) 0.4 18 (32.7%) 4 (20%) 0.3
Variant allele A 25 (11.5%) 24 (16%) 0.2 19 (17.3%) 5 (12.5%) 0.4
CCR5Δ32
wt/wt 88 (80.7%) 57 (76%) 39 (70.9%) 18 (90%)
wt/Δ32 21 (19.3%) 18 (24%) 0.4 16 (29.1%) 2 (10%) 0.1
Δ32/Δ32 00 0 0
Variant allele Δ32 21 (9.6%) 18 (12%) 0.5 16 (14.5%) 2 (5%) 0.1
• HIV-1 TP: HIV-1-infected typical progressors
• HIV-1 LTNP: HIV-1-infected long-term nonprogressors
• HIV-1 LTNP-DVL: HIV-1-infected long-term nonprogressors with detectable plasma viral load
• HIV-1 LTNP-EC: HIV-1-infected long-term nonprogressors with undetectable plasma viral load
• wt indicates wild-type allele; Δ32, 32 bp deletion
* χ2 test or Fisher exact test when necessary. p value arises from the comparison between HIV-1 TP and HIV-1 LTNP.
** χ2 test or Fisher exact test when necessary. p value arises from the comparison between HIV-1 LTNP-DVL and HIV-1 LTNP-EC.Veloso et al. BMC Medical Genetics 2010, 11:63
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Both genotype and allele analyses indicated that there
were no differences in the distribution of the genetic vari-
ants between LTNP and TP (Table 3). When we analysed
the LTNP subset of patients and compared the elite con-
trollers with those with detectable viral loads, we found
that the TNF-α-238A  genetic variant was significantly
overrepresented in elite controllers: p = 0.02 for genotype
analyses and p = 0.03 for allele analyses (Table 3). The
results obtained in the full cohort for all these analyses
were maintained when the individuals carrying the
CCR5Δ32 variant allele were excluded.
TNF-α haplotype analyses indicated that there was a
significant association between carriage of the haplotype
3 and the risk of infection (p = 0.04) (Table 4). No signifi-
cant associations were observed with disease progression
in infected individuals (Table 5). It should be noted that
the EU subset could not be included in the analyses
because of the low number of individuals in our cohort.
CCR5 Δ32
There were no significant differences in the prevalence of
the CCR5Δ32 genetic variant allele among the different
categories of patients assessed (Tables 2 and 3). CCR5Δ32
homozygosity was not detected.
Discussion
I n  t h i s  c o h o r t  o f  C a u c a s i a n  S p a n i a r d s ,  w e  f o u n d  t h a t
TNF-α gene polymorphism may be involved in vulnera-
bility to HIV-1 infection. In infected patients, none of the
TNF-α genetic variants assessed influences disease pro-
gression, but the TNF-α-238G>A  SNP may modulate
viremia control in LTNP. Carriage of the CCR5Δ32 vari-
ant allele does not influence the risk of infection or dis-
ease progression.
To explain the variable interindividual vulnerability to
HIV-1 infection, we sought a genetically-driven host sus-
ceptibility. Several candidate genes were checked, one of
which was TNF-α  because of its robust role in initial
response to infection influences both innate and acquired
immunity [1,3,31,32]. Our data indicate that none of the
individual polymorphisms assessed influence vulnerabil-
ity to HIV-1 infection, but haplotype analyses suggest
that the combination of some genetic variants within the
TNF-α gene may modulate the risk of infection. These
results agree with some reports that showed an associa-
tion between TNF-α SNP and the risk of infection [10,12];
other investigations, however, observed no significant
associations [11,13-15]. The discrepancy between our
findings and those reported previously may be because of
the low number of patients assessed in some studies [15],
which often provides unstable data [33], or because the
different ethnicities of the people assessed in others
[13,14] may have led to genuine population differences
[34].
Other reports have investigated the involvement of
TNF-α  genetic variants in a variety of immunogenetic
events that affect HIV-1 disease progression. Some stud-
ies have related the risk of progression [10-12,16,17] and/
or of developing a diversity of AIDS-related events [35-
41] with carriage of some TNF-α genetic variants while
others, like ours, have failed to find any significant associ-
ation [14,15]. In this respect, our study suggests that there
are no significant associations between TNF-α  genetic
variants and disease progression. To assess this issue we
used a cohort of TP as controls and a subset of LTNP of
Table 4: TNF-α haplotypes and risk of HIV-1-infection.
Haplotypes TNF-α SNP n (estimated frequencies in %) OR OR 95CI% p value *
-238 G>A -308 G>A -863 G>A Total 
(n = 373)
Uninfected 
(n = 189)1
HIV-1-Infected 
(n = 184)
H1 G G C 246 
(65.98%)
115 
(61.45%)
131 (70.73%) 1.00
H2 G G A 54 (14.46%) 31 (16.66%) 23 (12.51%) 1.47 0.95 - 2.30 0.09
H3 G A C 48 (13.07%) 29 (15.36%) 19 (10.45%) 1.65 1.04 - 2.64 0.04
H4 A G C 21 (5.45%) 10 (5.13%) 11 (5.99%) 1.03 0.52 - 2.04 0.94
rare * * * 5 (1.04%) - - 1.46 0.23 - 9.47 0.69
Note: The exposed uninfected subset of patients could not be included in the analysis because of the low number of individuals available.
1Of 203 healthy uninfected controls individuals, only 189 had the three TNF-α SNPs assessed.
* p value for comparisons of each haplotype with a frequency greater than 1% with the most common haplotype (H1)Veloso et al. BMC Medical Genetics 2010, 11:63
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over 16 years' duration as cases. This extreme LTNP phe-
notype was expressly chosen to prevent groups from
superposing. Of particular note, however, was that within
the LTNP group we showed a significant association
between carriage of the TNF-α-238A variant allele and
the spontaneous "elite controller" phenotype. This repli-
cates what was reported in an early study [16] but, since
this finding is supported by a very small number of
patients it should be further replicated in larger series of
this uncommon subset of HIV-1-infected patients.
For CCR5Δ32, we found that there is no signal for non
progression. This is in agreement with CCR5Δ32 having a
primary effect against rapid progression as pointed out by
the GRIV study [42,43]. We acknowledge, however, that
in order to see the effect of CCR5Δ32, the use of a larger
cohort and/or a Kaplan-Meier plot of patients' evolution
since seroconversion under various endpoints could have
been useful.
Our study has some limitations. First, the cross sec-
tional nature of the design provides associations, not cau-
sality. Second, the comparison of the LTNP with the TP
subsets is rather limited since it involves long-term non
progression and not simple progression, and additional
analyses with Kaplan-Meier curves (with various end-
points such as death or AIDS 1993 criteria) could lead to
different results. Finally, some of the subsets assessed
were small, particularly the exposed uninfected and elite
controllers. This means that our analyses of these subsets
may be too underpowered to detect other significant
associations.
Conclusions
In summary , in a cohort of Caucasian Spaniards, poly-
morphism within the TNF-α gene may be associated with
vulnerability to HIV-1 infection. In infected patients,
none of the TNF-α genetic variants assessed influences
disease progression but the TNF-α-238G>A  SNP may
modulate the elite controller status. The CCR5Δ32 vari-
ant allele influences neither the risk of infection nor dis-
ease progression.
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Table 5: TNF-α haplotypes and disease progression in HIV-1-infected patients.
Haplotypes TNF-α SNP n (estimated frequencies in %) OR OR 95CI% p value *
-238 G>A -308 G>A -863 G>A Total 
(n = 184)
HIV-1 TP 
(n = 109)
HIV-1 LTNP 
(n = 75)
H1 G G C 131 (70.73%) 80 (73.44%) 51 (66.70%) 1.00
H2 G G A 23 (12.51%) 12 (9.90%) 11 (16.04%) 1.83 0.92 - 3.64 0.09
H3 G A C 19 (10.45%) 12 (9.83%) 7 (9.95%) 1.20 0.60 - 2.41 0.61
H4 A G C 11 (5.99%) 5 (4.25%) 6 (7.30%) 1.84 0.68 - 4.95 0.23
rare * * * 0 (0.32%) - - 1.00 - 1.00
* p value for comparisons of each haplotype with a frequency greater than 1% with the most common haplotype (H1)
HIV-1 TP: HIV-1-infected typical progressors
HIV-1 LTNP: HIV-1-infected long-term non-progressorsVeloso et al. BMC Medical Genetics 2010, 11:63
http://www.biomedcentral.com/1471-2350/11/63
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